Table 2. Pathway Analysis of the candidate genes in the GRASP cohort.

Ingenuity Pathway analysis depicting the top five pathways on exploring the 87 genes reported in Mak et al (7) study using the SKAT-O method in all SSc and diffuse subset of SSc patients. The Ingenuity Pathway Analysis program was used for predicting pathways. P-values were calculated using a right-tailed Fisher’s exact test. P-values were corrected for multiple testing using the Benjamini-Hochberg correction.

Ingenuity Pathway	PUnCorr	PCorr
All SSc patients as compared to controls
Hepatic Fibrosis / Hepatic Stellate Cell Activation	2.09 × 10−6	1.95 × 10−4
Melatonin Degradation III	0.005	0.22
Coagulation System	0.01	0.29
Complement System	0.01	0.29
Atherosclerosis Signaling	0.02	0.34
Diffuse subset of SSc patients as compared to controls
Hepatic Fibrosis / Hepatic Stellate Cell Activation	2.27 × 10−6	2.14 × 10−4
Melatonin Degradation III	0.005	0.22
Coagulation System	0.01	0.29
Complement System	0.01	0.29
Atherosclerosis Signaling	0.02	0.36

P_UnCorr Right-tailed Fisher’s exact p-value

P_Corr Multiple test-corrected P-values using the Benjamini-Hochberg correction